Saturday 17 October 2026
Export COO’s income statement to Excel — free account
The Cooper Companies, Inc.
COO Healthcare Medical Instruments & Supplies
The Cooper Companies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $4.1 billion, up 5.06% from fiscal 2024. In the quarter to July 2026, revenue was flat, EPS grew 357.1%, free cash flow grew 66.0% and total debt rose 2.66%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.
57.94
0.54
+0.94%
Follow COO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to October
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 29.82 | 43.51 | 54.12 | 60.43 | 59.17 | 88.26 | 61.06 | 75.94 | 84.76 | 61.78 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 47.75 | 64.10 | 70.80 | 86.08 | 92.90 | 115.90 | 107.67 | 99.91 | 112.38 | 100.24 | |||||
| People | |||||||||||||||
| People | Employees | 10,600 | 11,800 | 12,000 | 12,000 | 12,000 | 12,000 | 14,000 | 15,000 | 16,000 | 15,000 | ||||
| Revenue/emp, $m | 0.19 | 0.18 | 0.21 | 0.22 | 0.20 | 0.24 | 0.24 | 0.24 | 0.24 | 0.27 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 1,967 | 2,139 | 2,533 | 2,653 | 2,431 | 2,923 | 3,308 | 3,593 | 3,895 | 4,092 | ||||
| Gross margin, % | 59.65 | 63.85 | 64.45 | 66.21 | 63.14 | 66.92 | 64.67 | 65.62 | 66.64 | 65.54 | |||||
| EBT | 296 | 394 | 332 | 477 | 267 | 492 | 475 | 413 | 582 | 567 | |||||
| EBT margin, % | 15.03 | 18.42 | 13.10 | 17.99 | 10.96 | 16.82 | 14.37 | 11.49 | 14.95 | 13.84 | |||||
| Net income | 275 | 373 | 140 | 467 | 238 | 2,945 | 386 | 294 | 392 | 375 | |||||
| Depreciation | 198 | 188 | 275 | 281 | 287 | 309 | 346 | 368 | 375 | 377 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 10.14 | 10.94 | 12.90 | 13.43 | 12.38 | 14.85 | 16.76 | 18.16 | 19.58 | 20.55 | ||||
| Earnings | 1.40 | 1.88 | 0.70 | 2.33 | 1.20 | 14.79 | 1.94 | 1.48 | 1.96 | 1.87 | |||||
| Cash flow | 2.63 | 3.03 | 3.41 | 3.61 | 2.48 | 3.75 | 3.51 | 3.07 | 3.57 | 4.00 | |||||
| Capex | (0.79) | (0.65) | (0.99) | (1.48) | (1.58) | (1.09) | (1.23) | (1.98) | (2.12) | (1.82) | |||||
| Free cash flow | 1.84 | 2.38 | 2.42 | 2.13 | 0.90 | 2.66 | 2.28 | 1.09 | 1.45 | 2.18 | |||||
| Book value | 13.90 | 16.24 | 16.84 | 18.36 | 19.47 | 35.27 | 36.35 | 38.16 | 40.64 | 41.38 | |||||
| Shares, m | 194 | 196 | 196 | 198 | 196 | 197 | 197 | 198 | 199 | 199 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 31.49 | 31.95 | 92.92 | 31.16 | 66.64 | 7.12 | 35.23 | 52.75 | 53.68 | 37.19 | ||||
| P/S | 4.34 | 5.49 | 5.01 | 5.42 | 6.47 | 7.10 | 4.08 | 4.29 | 5.35 | 3.40 | |||||
| P/B | 3.17 | 3.70 | 3.83 | 3.96 | 4.11 | 2.99 | 1.88 | 2.04 | 2.58 | 1.69 | |||||
| EV/Sales | 4.97 | 6.00 | 5.78 | 6.07 | 7.16 | 7.58 | 4.87 | 4.97 | 5.98 | 3.99 | |||||
| EV/FCF | 27.37 | 27.52 | 30.78 | 38.26 | 98.84 | 42.25 | 35.78 | 83.13 | 80.86 | 37.62 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 510 | 594 | 669 | 713 | 487 | 739 | 692 | 608 | 709 | 796 | ||||
| Capex | (153) | (127) | (194) | (292) | (310) | (214) | (242) | (392) | (421) | (362) | |||||
| Free cash flow | 357 | 466 | 475 | 421 | 176 | 524 | 450 | 215 | 288 | 434 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 394 | 557 | 554 | 53 | 270 | 733 | 253 | 736 | 929 | 994 | ||||
| Total debt | 1,334 | 1,173 | 2,023 | 1,826 | 1,793 | 1,481 | 2,763 | 2,569 | 2,584 | 2,505 | |||||
| Net debt | 1,233 | 1,084 | 1,945 | 1,737 | 1,677 | 1,385 | 2,625 | 2,448 | 2,476 | 2,395 | |||||
| Shareholders’ equity | 2,696 | 3,176 | 3,308 | 3,629 | 3,825 | 6,942 | 7,175 | 7,551 | 8,084 | 8,239 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 6.13 | 7.99 | 2.55 | 7.54 | 3.66 | 36.03 | 3.66 | 2.54 | 3.27 | 3.03 | ||||
| ROIC | 5.16 | 6.30 | 4.80 | 6.37 | 3.54 | 3.80 | 3.24 | 3.33 | 4.18 | 4.01 | |||||
| ROE | 10.20 | 12.70 | 4.32 | 13.46 | 6.40 | 54.70 | 5.47 | 4.00 | 5.02 | 4.59 | |||||
Negative figures in brackets.
Fiscal years to Oct 2025 · latest quarter Jul 2026
Charts ten years each
The Cooper Companies, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SOLV Solventum Corporation | $15.0B | 10.4× | 39.0× | +2.22% (above 0%: growing) | +1.92% (above 0%: growing) | +144.07% (above 0%: growing) | 58.22% | 8.19% | Compare |
| BAX Baxter International Inc. | $13.3B | — (loss-making) | 44.7× | +5.34% (above 0%: growing) | +33.33% (above 0%: growing) | +119.48% (above 0%: growing) | 34.86% | 7.33% | Compare |
| RGEN Repligen Corporation | $11.7B | 234× | 112× | +11.93% (above 0%: growing) | −65.38% (below 0%: shrinking) | +27.10% (above 0%: growing) | 53.91% | 6.85% | Compare |
| COO The Cooper Companies, Inc. | $10.9B | 19.8× | 28.7× | +0.56% (above 0%: growing) | +357.14% (above 0%: growing) | +65.96% (above 0%: growing) | 66.77% | 20.82% | |
| AVTR Avantor, Inc. | $10.9B | — (loss-making) | 25.5× | +0.53% (above 0%: growing) | −33.33% (below 0%: shrinking) | +12.66% (above 0%: growing) | 31.73% | 7.20% | Compare |
| ALGN Align Technology, Inc. | $10.6B | 25.6× | 20.7× | +4.32% (above 0%: growing) | −12.21% (below 0%: shrinking) | +85.77% (above 0%: growing) | 71.71% | 14.58% | Compare |
| ATR AptarGroup, Inc. | $7.9B | 22.2× | 21.0× | +6.26% (above 0%: growing) | −18.34% (below 0%: shrinking) | −23.07% (below 0%: shrinking) | 35.61% | 12.34% | Compare |
| BLCO Bausch + Lomb Corporation | $6.0B | — (loss-making) | — (loss-making) | +9.08% (above 0%: growing) | n/m | +251.85% (above 0%: growing) | 62.20% | 5.95% | Compare |
| TFX Teleflex Incorporated | $5.4B | — (loss-making) | 45.3× | +28.88% (above 0%: growing) | −17.33% (below 0%: shrinking) | +220.14% (above 0%: growing) | 58.16% | 12.77% | Compare |
| Median of peers | $10.7B | 23.9× | 39.0× | +5.80% | −17.33% | +102.63% | 56.04% | 7.76% |
COO metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
The Cooper Companies, Inc. (COO) key facts
- Concern: Net income was $374.9 million, or $1.87 per share (basic), a net margin of 9.16%.
- Strength: The Cooper Companies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $4.1 billion, up 5.06% from fiscal 2024.
- The Cooper Companies, Inc. (COO) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, COO traded at $57.94, a market capitalization of $10.9 billion.
- At that price the stock trades at 19.8× trailing-twelve-month earnings and 2.6× sales; its P/E is higher than 13% of its own readings over the past ten years.
- Return on equity was 4.59% and debt-to-equity 0.31.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.48 (safe zone) for fiscal 2025.